Senior DIrector
Evidera, Inc
Boston, Massachusetts, United States
Dr. Meredith Smith is Risk Management Director at Alexion, Inc. where she leads a team responsible for medicinal product benefit-risk management. She is a behavioral scientist and health services researcher by training with a professional background in public health and health outcomes research, and has over 15 years of experience in the pharmaceutical industry. She has served on numerous FDA expert panels, on CIOMS Working Groups VIII, IX and XI, and is currently Industry Lead of the Small Lung Cancer Case Study, and Patient Communications workstream for IMI-PREFER. She is a board member of the Rutgers University BioPharma Educational Initiative in the School of Health Professions, and an adjunct professor at the University of Southern California School of Pharmacy. In terms of professional service, she has served as Co-Chair of ISPE’s BRACE SIG, is currently Co-Lead of Website Content for ISPE’s RWE Taskforce, Co-Chair of the ISPE Public Policy Committee, and is Pharmacovigilance Track Chair for the 2021 DIA Annual Meeting Planning Committee. She has published widely in the peer-reviewed research literature on health outcomes assessment in oncology and HIV, patient communication, drug safety and medicinal product benefit-risk assessment and management, with particular focus on the application of implementation science to risk minimization.
AstraZeneca (Employment, Ownership Interest includes stock, stock options, patent or other intellectual property, Dr. Smith also owns stock in Amgen, AbbVie and Bristol-Myers Squibb)
Wednesday, August 24, 2022
8:30 AM – 12:30 PM CEST
Sunday, August 28, 2022
8:30 AM – 10:00 AM CEST
Sunday, August 28, 2022
3:15 PM – 4:45 PM CEST